注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Fate Therapeutics Inc是一家臨床階段的生物製藥公司。該公司專注於為癌症患者開發程序化細胞免疫療法。該公司使用從其專有的iPSC產品平台產生的人類誘導多能幹細胞(iPSCs)來創建具有首選生物學特性的基因工程克隆主iPSC系。該公司正在推進一系列程序化細胞免疫療法,包括來自克隆主iPSC線的現成自然殺傷細胞(NK)和T細胞候選產品,用於治療癌症。該公司的產品管線包括FT596、FT538、FT576、FT536、FT573、FT819、FT500、FT516。FT516是一種研究性現成的NK細胞癌免疫療法,源自克隆主iPSC線,被設計用於表達新的CD16(hnCD16)Fc受體。FT596是一種研究性現成的CAR NK細胞癌免疫療法,源自克隆主iPSC線。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
J. Scott Wolchko | 52 | 2013 | Founder, CEO, President & Director |
John D. Mendlein | 62 | 2007 | Independent Vice Chairman of the Board |
William H. Rastetter | 74 | 2011 | Independent Chairman |
Robert S. Epstein | 67 | 2014 | Independent Director |
Timothy P. Coughlin | 55 | 2013 | Independent Director |
Robert M. Hershberg | 60 | 2020 | Independent Director |
Shefali Agarwal | 48 | 2019 | Independent Director |
Yuan Xu | 53 | 2021 | Independent Director |
Sean J. Morrison | - | 2010 | Member of Scientific Advisory Board |
Lynn Megeney | - | 2010 | Member of Scientific Advisory Board |
Robert S. Langer | 74 | - | Member of Scientific Advisory Board |
Sui Huang | - | 2010 | Member of Scientific Advisory Board |
Stuart Orkin | - | 2010 | Member of Scientific Advisory Board |
Bennett M. Shapiro | 83 | - | Member of Scientific Advisory Board |
Mark Krasnow | - | 2010 | Member of Scientific Advisory Board |
Karin Jooss | 58 | 2019 | Independent Director |
Alberto Hayek | - | 2010 | Member of Scientific Advisory Board |
Steven L. Goldstein | - | 2010 | Member of Scientific Advisory Board |
Michael Stewart Lee | 44 | 2018 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核